Fresenius Kabi announced the launch of Daptomycin for Injection, the generic version of Merck‘s Cubicin.

Daptomycin is a lipopeptide antibacterial which is indicated for the treatment of complicated skin and skin structure infections and Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. 

Related Articles

Daptomycin binds to bacterial cell membranes and causes a rapid depolarization of membrane potential. This loss of membrane potential causes inhibition of DNA, RNA, and protein synthesis, which results in bacterial cell death.

Fresenius Kabi’s Daptomycin for Injection is available as a single dose vial containing 500mg/vial.

For more information visit